BACKGROUND: After increased requests for biopsies for clinical trials and biomarker research, the University of Pittsburgh Medical Center created a clinical trial research service that partnered pathology, radiology, and medicine to facilitate rapid on-site evaluation (ROSE) of fine-needle aspiration (FNA) and/or core needle biopsy (CNB) samples to confirm the presence of tumor in these studies. METHODS: Clinical trial coordinators organized biopsies for patients needing tumor samples for trials, and informed the cytopathology and radiology team. ROSE was performed to confirm the presence of sufficient tumor in FNA specimens and/or touch preparations of CNB. RESULTS: A total of 79 cases from a total of 14 clinical trials were evaluated with ROSE, 77 of which (97%) were for research only. There were 53 cases (67%) from breast/ovarian cancer studies that were initiated between 2008 and 2009, whereas 26 cases (33%) included a variety of other tumors for studies that were started between 2011 and 2014. The majority required CNB samples (60 cases; 76%), 20% of which used an FNA for needle placement before obtaining CNB material and 56% of which had touch preparations of the CNB evaluated without a preceding FNA. The concordance rate for ROSE with final adequacy of the sample was 96% to 100%. CONCLUSIONS: The study institution has experienced an increase in the number of clinical trial studies requesting ROSE to confirm the presence of tumor in a variety of malignancies. Cytology laboratories can help with patient care by offering ROSE to determine the adequacy of clinical trial material to minimize the submission of unsatisfactory or nonrepresentative material. Developing a clinical research service enhances communication and the processing of novel research specimens for cancer patients. Cancer Cytopathol
INTRODUCTION
In this era of personalized medicine, the increase in targeted therapies for solid tumors has consequently led to an increase in the demand for molecular testing. In addition, there is great interest in new biomarker research to discover new potential targets for treatment, and to find markers that are associated with critical theranostic information for patients with cancer. Recently, substantial improvements in outcomes have resulted from targeted therapies administered to patients selected by biomarkers, thereby transforming patient care for several cancer types. [1] [2] [3] [4] [5] Accordingly, clinical trials for biomarker research are requesting that tumor tissue be collected for the determination of patient eligibility for new targeted therapies and for the investigation of novel biomarkers. 6, 7 The rise in the number of clinical trial studies requesting confirmation of tumor cell content has, in turn, increasingly demanded rapid on-site evaluation (ROSE) to ensure viable tumor cell content and to avoid nondiagnostic results, false-negative results, or the need for repeat biopsies. In addition, there is a need in some studies for fresh tissue to be processed immediately at the time of the biopsy. This emphasis on quality tissue collections in biomarker-driven research has been recognized by the American Society of Clinical Oncology, which advocates for comprehensive biospecimen banks for each trial that then can be used for these critical clinical studies that provide the gold standard for defining cancer therapies for patients. 8 There also are specific guidelines, known as the Biospecimen Reporting for Improved Study Quality (BRISQ) recommendations, that emphasize the importance of thorough and standardized procedures for biospecimen preanalytical protocols to improve the quality of the clinical or research data obtained from them. 7 Furthermore, in trials examining lung cancer therapies, archival tissue from diagnostic material typically is insufficient in quality or quantity for additional biomarker research, thereby necessitating that additional tissue be procured for research purposes only. Some trials also require fresh, unfixed tissue for enrollment, which is very labor-intensive and involves collaboration with numerous departments, such as oncology, pathology, and radiology. 9 Due to the wide spectrum of requirements for diverse trials, a major challenge for cancer centers is the collection of high-quality tissue samples with adequate cellularity. 7, 10 Thus, coordination among these hospital departments is crucial to optimize the possibility that patients with cancer will have sufficient tissue obtained that meets all requirements for enrollment in these important clinical trials. 2, 7, 9 In response to these demands, the University of Pittsburgh Medical Center has created a multidisciplinary clinical research service, which partners the oncology clinical team with the departments of pathology and radiology, in addition to the institutional tissue bank to facilitate the evaluation of fine-needle aspiration (FNA) and/or core needle biopsy (CNB) samples using ROSE for research and clinical trial purposes. The objective of the current study was to characterize the volume and complexity of studies requesting clinical trial cytopathology services for ROSE, and to determine the impact of this service at a tertiary care medical center.
MATERIALS AND METHODS
Clinical trial coordinators obtained study materials, protocols, and institutional review board (IRB) approval information for all studies, and notified the departments involved at the time of IRB acceptance and before study enrollment. Patients who required fresh tumor tissue samples for eligibility or enrollment in clinical trials and other research studies then were scheduled at the University of Pittsburgh Medical Center and Hillman Cancer Center in Pittsburgh, Pennsylvania, after seeing a medical oncologist. Clinical trial coordinators informed the divisions of cytopathology and interventional radiology, in addition to the institutional tissue bank regarding: 1) patient consent; 2) the clinical trial number and title; 3) the principal investigator; 4) the indication for biopsy (research/clinical trial and/or diagnosis); 5) the type of sample to be collected (FNA and/or CNB); 6) other protocol specifications including needle gauge, number of specimens required, desired tumor content, and specimen handling for submission; and 7) the date the image-guided biopsy was scheduled (Table 1) (Fig. 1) . 
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Specimens were collected as per 1 of 3 methods to meet research protocol requirements: 1) FNA only for the determination of correct needle placement with ROSE confirming the presence of tumor, and the collection of additional passes without ROSE according to the research protocol (FNA only); 2) CNB with touch preparation (TP) only for confirmation of a representative tumor sample with ROSE of TP, and the collection of additional CNB specimens (without TP or ROSE) as per the research protocol (CNB only); or 3) FNA with ROSE for the determination of correct needle placement and subsequent CNB with or without TP for additional tumor samples, as needed for the applicable protocol (FNA and CNB). Some clinical trials requested serial fresh biopsy specimen collections during both the pretreatment and posttreatment time points. In some studies that requested serial biopsies of the same lesion, subsequent biopsies were aborted or cancelled if there was no targeted lesion remaining (eg, clinical complete response) or if the patient was lost to follow-up.
All image-guided biopsies were performed by the interventional radiology department, involving interventional radiologists, or a physician assistant supervised by an attending interventional radiologist. Image-guided biopsies were performed after the radiology department obtained written informed consent for an independent procedure. Standard local anesthesia (lidocaine) was applied for these radiology procedures, and conscious sedation was used if needed.
ROSE of FNA specimens and/or TPs of CNB samples was performed by a board-certified cytopathologist. ROSE of FNA specimens is a well-established method for ensuring the adequacy of lesion sampling. [11] [12] [13] [14] [15] [16] [17] [18] Several studies also have assessed the impact of TPs from CNB samples and the value of immediate on-site evaluation. [11] [12] [13] [14] [15] Following the recommendations from these studies, the study institution prepared FNA specimens and TPs with only a limited amount of material and without significant tissue manipulation to preserve material. FNA and TP slides were air-dried and immediately stained with Diff-Quik by an on-site cytotechnologist. The slides then were reviewed by a board-certified cytopathologist. Specimens were deemed adequate when samples or TPs contained sufficient qualitative and quantitative material for a malignant diagnosis. Although there was not a strict quantitative cutoff value, if there were scant viable tumor cells or extensive necrosis, this then was communicated to the proceduralist so that additional material (eg, extra FNA passes or additional CNB samples) could be obtained to minimize the possibility of inadequate material. If the sample was determined to be inadequate at ROSE and if permitted by the research protocol, additional passes were performed and evaluated until the cytopathologist classified the material as adequate or until the radiologist terminated the procedure due to patient discomfort or for safety reasons. Documentation of ROSE was provided by the cytopathologist, along with the prepared slides and specimens for submission. In cases with insufficient viable material or a lack of tumor cells, additional biopsies from different areas of the lesion or alternative lesions were considered and performed, if safe and agreeable to the patient, before excluding the patient from clinical trial eligibility. In some studies examining posttreatment samples, material was submitted regardless of cellularity, depending on study specifications. The stained FNA specimens and TP slides were submitted with accompanying paperwork to the research study staff or institutional tissue bank, depending on the study specifications, for archiving and submission to the clinical trial. Subsequent biopsy material either was placed into RNAlater (Qiagen, Inc, Germantown, Md.), formalin, or ethanol, or was snap frozen with dry ice or liquid nitrogen. Clinical trial coordinators were present at the time of the biopsy procedure and brought the appropriate supplies and labels necessary for the specified processing. These trial coordinators also kept meticulous details regarding the time the biopsies were obtained and any other specific data required for the study. If materials for handling and processing of the specimens (eg, liquid nitrogen) were not provided by the study, arrangements were made with the institutional tissue bank to supply such processing materials and staff. For clinical trials requiring the submission of formalin-fixed, paraffin-embedded (FFPE) blocks from fresh tissue biopsies, CNB specimens were fixed in 10% neutral-buffered formalin and promptly delivered in person by the clinical trial coordinators to the institutional tissue bank for processing and subsequent analysis of tumor cellularity of fixed tissue in the FFPE block by a boardcertified pathologist. A quantitative measure of tumor cellularity was not provided onsite; rather, only a qualitative analysis of whether tumor was present or absent was provided. If samples, particularly posttreatment samples, were extensively necrotic, this also was discussed with the radiology department to try to optimize the sample by obtaining additional material or sampling of another area in an effort to provide the trial with the greatest tumor viability and least necrosis. The studies and trials included a variety of different testing on the acquired tumor tissue, including BRCA mutation testing in breast carcinomas, tumor assessment of a variety of different genes and proteins, and pharmacokinetic studies.
For patients requiring specimen collection for diagnostic workup by the pathology department, in addition to the clinical trial or research submission, samples for diagnosis were collected first and processed by standard procedures and clinical workflow, including accessioning into our pathology laboratory information system. Cases for research only were not accessioned into our pathology laboratory information system, but paper documentation was archived in the cytopathology laboratory and/or institutional tissue bank.
RESULTS
A total of 79 cases from 56 patients involving 14 clinical trials were evaluated with ROSE. Each clinical trial enrolled an average of 4 patients (range, 1-19 patients; mode 1). Of the 79 cases, 53 (67%) were from 2 breast cancer trials (14% of the total studies) that were established in 2008 and 2009, respectively. The remaining 26 cases (33%) were from 12 studies (86% of the total studies) enrolling patients with a variety of tumors and these were established in 2011 or later. Overall, the cases involved patients with a variety of different advanced or metastatic tumors including breast cancer (3 cases), pancreatic cancer (1 case), squamous cell carcinoma (5 cases), small cell lung carcinoma (1 case), non-small cell lung carcinoma (2 cases), colorectal carcinoma (2 cases), and a variety of cancer types (1 case). One trial included colorectal cancer and head and neck squamous cell carcinoma (1 case). The 
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Cancer Cytopathology biopsy sites requested for sampling included lymph node (3 cases), lung (3 cases), liver (3 cases), or a choice of a variety of metastatic sites (5 cases). Only 5 of the 14 trials (36%) specified that there was centralized review before treatment/ enrollment. In addition, 4 of the 14 trials (29%) specified that specimens were needed at different time points, including pretreatment, and then again while patients were receiving treatment and/or had completed treatment.
Among the 79 cases evaluated by ROSE, 77 (97%) were for research purposes only and 2 (3%) were for both research and diagnostic purposes. Table 2 highlights the reasons for ROSE of these biopsies. A total of 26 patients (46%) had > 1 biopsy performed at different time points designated by the research protocol. The majority of cases (60 of 79 cases; 76%) required CNB material for the study, 16 of which (20%) used an FNA for correct needle placement before obtaining CNB material. The remaining 44 cases (56%) had TPs of the CNB evaluated. In cases requesting CNB, a range of 1 to 6 cores was requested, and 1 of these studies specified that the cores should be 18-gauge. The majority of studies (>79%) requested between 2 and 6 cores. In addition, 4 studies requested fresh tissue to be frozen or placed in RNAlater (Qiagen, Inc, Germantown, Md.), whereas 9 studies only required FFPE tissue and 1 study requested FFPE tissue with the option of also submitting fresh tissue when available. Table  3 summarizes the findings in these 79 cases.
Of the 79 biopsies evaluated, 56 (71%) had followup data available from the clinical trial. Of these cases, 48 (86%) were confirmed to have tumor present at the time of ROSE and 2 had "atypical cells present" (3.6%), whereas 6 cases (10.7%) did not have definitive tumor present at the time of ROSE. A total of 46 cases with tumor present at the time of ROSE had sufficient tumor for the clinical trial testing (96% concordance). Only 2 cases deemed adequate at ROSE subsequently were found to have insufficient tumor present for further evaluation. In addition, 2 of the cases (with "atypical cells present") had sufficient tumor on the final specimen for the clinical trial, and all of the cases without definitive tumor at ROSE had no tumor noted on the final specimen (100% concordance) (Fig. 2) . In addition, of the 4 trials requiring posttreatment biopsies (29%), there were 5 of 16 cases (31%) with known follow-up that had insufficient material at ROSE due to extensive necrosis; these cases were not sent to the clinical trial unless requested. Of the 8 cases with no definitive tumor found to be present at ROSE (2 atypical and 6 with no tumor), 6 were from studies with CNB samples evaluated by TP at ROSE, whereas only 2 were from studies with an FNA evaluated at ROSE.
DISCUSSION
The University of Pittsburgh Medical Center has experienced an increase in the number of clinical trial studies requesting fresh tissue biopsies with ROSE to confirm the presence of tumor in procured samples. Pathologist review of trial material at the time of acquisition is essential to confirm that viable tumor was obtained before submitting material in different media for research or clinical trials, and to avoid the patient having to return for additional procedures. This is particularly important given that only approximately 36% of the trials specified that there was centralized review before treatment/enrollment; thus, ROSE confirmation may be the only opportunity to guarantee lesional cells in the specimen before enrollment. After a pathologist confirms the presence of viable tumor in the FNA and/or CNB sample at the time of ROSE, the material is submitted for biomarker or clinical trial testing or other research and investigative studies. The results of the current study illustrate the ability of a multidisciplinary group incorporating individuals from oncology, radiology, and pathology to successfully orchestrate suitable tissue sampling and testing for patients with cancer who consent to participation in clinical trials and/or other research projects. This experience highlights the important role that cytopathology laboratories can play in this research effort. The current study data illustrate that there is a wide spectrum of studies recruiting patients for biomarker discovery and/or clinical trials, particularly at a large tertiary care medical facility with an active cancer center. Our trials started with enrollment for 2 breast cancer trials established in 2008 through 2009, and then expanded to include 12 additional studies established after 2011. These additional studies enrolled patients with multiple different types of tumors, particularly head and neck squamous cell carcinomas, lung carcinomas (non-small cell and small cell types), and colorectal carcinomas. Each of these studies had a slightly different protocol and tissue requirement with respect to numerous factors (eg, the number of CNB specimens required, the type of fixative, needle gauge, etc), which makes the coordination and adoption of a standard workflow challenging. In addition, the results of the current study indicate that the majority of studies recruited <5 patients and each extended over a time span of several years, at least in the early stages, which makes it further challenging to stay abreast of the requirements for each study. There also was a large lag time between study submission, study approval, and the start of enrollment. It has been shown that the requirement for repeat biopsies, tissue acquisition, and central biomarker testing results in significant delays in initiating study treatment and in patient attrition. 19 Thus, the current study demonstrates the benefit of having a dedicated group of staff members familiar with all studies who can serve as a central repository for information, IRB approvals, consent paperwork, and other study-related information. These nonphysician individuals also help link the patient with cancer to the necessary team members in radiology and pathology, who are instrumental in getting their tumor sample where it needs to go. To make this happen seamlessly, we believe that the group approach we used was necessary and provided assurance that there was a strong bridge between the patient and the multidisciplinary group.
Other institutions, such as the University of California at Los Angeles, also have reported on the value of having a dedicated group of individuals from various departments, including medical oncology, pathology, and radiology, available to coordinate clinical trials that require tumor tissue for enrollment. 3 The data from the University of California at Los Angeles, McGill University in Montreal, and other institutions also illustrate how laborintensive it is to ensure that patients have adequate material for these trials, particularly when the trial requires fresh, unfixed tissue. 10, 20 The American Society of Clinical
Oncology recognizes the importance of having comprehensive biospecimen banks for biomarker discovery trials, which involves having the appropriate IRB approvals, informed consent from patients, and coordination within Original Article
Cancer Cytopathology 486 hospitals for obtaining these biopsies. 8 There also are guidelines for human biospecimen collections for clinical or research purposes. 7 Given the importance of high-quality tissue acquisition for these trials, cytopathology laboratories can play a key role in evaluating these biopsies to maximize patient eligibility and minimize nondiagnostic specimens on the front end. In terms of small biopsy acquisition for these studies, minimally invasive biopsy techniques using small needle gauges are critical to minimize patient discomfort and maximize patient safety, especially given that these are patients with cancer who typically have had a history of multiple biopsies or surgical resections for diagnosis and treatment. Other institutions, such as Johns Hopkins University in Baltimore and The University of Texas MD Anderson Cancer Center in Houston, have demonstrated that research biopsies can be performed safely with a high rate of successful tissue collection. 21, 22 Therefore, the current study at the University of Pittsburgh Medical Center illustrates that creating a streamlined, safe, and efficient process for repeat tissue acquisition for research or clinical trials alone can make a significant difference to a patient with cancer because there is a great deal of information required for these research biopsies, as highlighted in Figure 1 and Table 1 . In general, it has been well established that ROSE of FNA and CNB TP optimizes the ability to obtain adequate lesional material at the time of biopsy acquisition; however, some institutions may not have the capacity to provide ROSE for biopsies, which may limit availability. 1, 4, 6, 10, 11, [13] [14] [15] [16] [17] FNA is advantageous in that it is a minimally invasive technique that can be used in isolation to obtain material for these studies, or it can be used in conjunction with CNB to determine correct needle placement first (with FNA) to preserve the subsequent CNB material for research needs without having to manipulate the biopsy to also perform a TP. TPs also can be undertaken when CNB is the only biopsy needle to be used for obtaining lesional material. Other rapid evaluation methods for CNB include a frozen section of the CNB, but this tends to cause artifactual distortion of the cells, requires a longer processing time, and sacrifices tissue, which is why TP evaluations typically are preferred over frozen sections. The drawback of TP evaluation of a CNB and/or FNA evaluation at the time of ROSE is the potential for the loss of valuable cellular and DNA material. 12 To address this, once adequate lesional material is obtained, additional FNA passes or CNB can be performed in the same location to obtain untouched and unmanipulated material that is submitted entirely for study purposes. 11, 14, 18 In addition, when there is material from the FNA and CNB (when performed concurrently), there is the option to save more than 1 tissue block for later tests in the event that either of these blocks becomes depleted. Thus, the use of both biopsy techniques may be complementary and maximizes the material available for research while optimizing patient safety by avoiding a larger number of CNBs. Ensuring that the material meets the research protocol specifications for testing, ROSE has the potential to prevent repeat procedures and avoids delays in patient enrollment that otherwise would occur due to inadequate sampling. Furthermore, having cytopathologists on site performing ROSE is very valuable in cases in which tissue demonstrates mainly mucin or necrosis with scant tumor cells. In this particular situation, the on-site cytopathologists can directly provide interventional radiologists with recommendations to improve the likelihood of obtaining adequate tissue. The results of the current study demonstrate that posttreatment biopsies can be particularly problematic if the patient achieves a favorable response to treatment, because there may be scant viable cells. This was evident in the current study data, in which the highest unsatisfactory rates occurred in posttreatment biopsies. Thus, ROSE can help to minimize noninformative and false-negative data that can result from testing benign or necrotic tissue devoid of viable tumor cells, which in turn saves money and time by ensuring that the costly and labor-intensive research testing is performed on representative lesional material. ROSE also allows the cytopathologist to communicate with the proceduralist with regard to borderline or unsatisfactory cases to try to maximize the material from the biopsy. Table 2 highlights the advantages of ROSE for the evaluation of these small biopsies for research and clinical trial protocols. Other important factors to consider when developing study-specific workflows to meet clinical requirements for testing include the type, amount, and number of specimens to be collected. For example, performing an FNA initially with ROSE followed by CNBs without TP allows for better preservation of the core, which was particularly useful for lung specimens, which often are small and friable and have been reported to have greater tissue loss in comparison with TPs of other sites. 13 In addition, using an FNA for needle placement potentially causes less bleeding, is safer for the patient than a larger biopsy, allows the CNBs to be untouched, and also provides a cell block or aspirate material that could be used as additional study material, if acceptable. However, for larger lesions or superficial masses in other anatomic locations that are easier to biopsy, TPs performed on a CNB alone may be sufficient. Furthermore, ROSE is critical for protocols requiring rapid processing in multiple different media or containers to maximize the placement of representative tumor tissue in individual vials. Some trials have requested fresh tissue to minimize protein degradation or dephosphorylation, or to decrease nucleic acid degradation. Several components of the data collected regarding clinical trial cases warrant further investigation. One is the variability in different protocols and the need to have more detailed follow-up to correlate the pathologist's assessment with the downstream sufficiency rates for different tests. Although the exact tumor cellularity requirements may vary, with some studies requiring at least 50% of tumor cells and <25% necrosis, whereas others had different criteria and would be willing to proceed with tissue containing the greatest tumor percentage and least necrosis, it would be helpful to know whether there are more standardized protocols and cell requirements that could be used universally in similar studies. 6, 9 Better understanding of a trial's specific rationale for different types of tissue, and their inclusion or exclusion criteria, could help institutions to improve collection techniques and/or assessment methods on the front end. 23 The more the clinical trials can standardize protocols and provide more specific information for specimen collection, the easier this process can be for individual institutions and cancer centers that are experiencing an increase in these requests. 7 In addition, discussions between the institutional pathologists and those at the clinical trial laboratories could help to develop research protocols that are more practical for obtaining adequate material in the clinical setting. Other information that would be helpful would be the determination of whether there is any correlation between tumor size or type and the adequacy or inadequacy of samples. This would allow the radiology and pathology departments to choose lesions to be biopsied that are more likely to provide adequate samples upfront. Another consideration is examining complications or other adverse outcomes that may have occurred if multiple biopsies were requested. This is important given that some clinical trials may request up to 6 CNB specimens.
